Qun Yu, Yilin Zhang, Wenyun Zeng, Yingxin Sun, Xiaolu Zhang, Lin Guo, Yue Zhang, Bin Yu, Maojuan Guo, Yu Wang, Huhu Li, Yanrong Suo, Xijuan Jiang, Lili Song
{"title":"步阳黄酒煎剂通过调节高脂饮食载脂蛋白 E 缺乏小鼠的肠道微生物组和代谢物缓解动脉粥样硬化","authors":"Qun Yu, Yilin Zhang, Wenyun Zeng, Yingxin Sun, Xiaolu Zhang, Lin Guo, Yue Zhang, Bin Yu, Maojuan Guo, Yu Wang, Huhu Li, Yanrong Suo, Xijuan Jiang, Lili Song","doi":"10.4103/ejpi.EJPI-D-23-00031","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>The traditional Chinese herbal prescription Buyang Huanwu decoction (BHD), effectively treats atherosclerosis. However, the mechanism of BHD in atherosclerosis remains unclear. We aimed to determine whether BHD could alleviate atherosclerosis by altering the microbiome-associated metabolic changes in atherosclerotic mice. An atherosclerotic model was established in apolipoprotein E-deficient mice fed high-fat diet, and BHD was administered through gavage for 12 weeks at 8.4 g/kg/d and 16.8 g/kg/d. The atherosclerotic plaque size, composition, serum lipid profile, and inflammatory cytokines, were assessed. Mechanistically, metabolomic and microbiota profiles were analyzed by liquid chromatography-mass spectrometry and 16S rRNA gene sequencing, respectively. Furthermore, intestinal microbiota and atherosclerosis-related metabolic parameters were correlated using Spearman analysis. Atherosclerotic mice treated with BHD exhibited reduced plaque area, aortic lumen occlusion, and lipid accumulation in the aortic root. Nine perturbed serum metabolites were significantly restored along with the relative abundance of microbiota at the family and genus levels but not at the phylum level. Gut microbiome improvement was strongly negatively correlated with improved metabolite levels. BHD treatment effectively slows the progression of atherosclerosis by regulating altered intestinal microbiota and perturbed metabolites.</p>","PeriodicalId":519921,"journal":{"name":"Journal of physiological investigation","volume":"67 2","pages":"88-102"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Buyang Huanwu Decoction Alleviates Atherosclerosis by Regulating gut Microbiome and Metabolites in Apolipoprotein E-deficient Mice fed with High-fat Diet.\",\"authors\":\"Qun Yu, Yilin Zhang, Wenyun Zeng, Yingxin Sun, Xiaolu Zhang, Lin Guo, Yue Zhang, Bin Yu, Maojuan Guo, Yu Wang, Huhu Li, Yanrong Suo, Xijuan Jiang, Lili Song\",\"doi\":\"10.4103/ejpi.EJPI-D-23-00031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>The traditional Chinese herbal prescription Buyang Huanwu decoction (BHD), effectively treats atherosclerosis. However, the mechanism of BHD in atherosclerosis remains unclear. We aimed to determine whether BHD could alleviate atherosclerosis by altering the microbiome-associated metabolic changes in atherosclerotic mice. An atherosclerotic model was established in apolipoprotein E-deficient mice fed high-fat diet, and BHD was administered through gavage for 12 weeks at 8.4 g/kg/d and 16.8 g/kg/d. The atherosclerotic plaque size, composition, serum lipid profile, and inflammatory cytokines, were assessed. Mechanistically, metabolomic and microbiota profiles were analyzed by liquid chromatography-mass spectrometry and 16S rRNA gene sequencing, respectively. Furthermore, intestinal microbiota and atherosclerosis-related metabolic parameters were correlated using Spearman analysis. Atherosclerotic mice treated with BHD exhibited reduced plaque area, aortic lumen occlusion, and lipid accumulation in the aortic root. Nine perturbed serum metabolites were significantly restored along with the relative abundance of microbiota at the family and genus levels but not at the phylum level. Gut microbiome improvement was strongly negatively correlated with improved metabolite levels. BHD treatment effectively slows the progression of atherosclerosis by regulating altered intestinal microbiota and perturbed metabolites.</p>\",\"PeriodicalId\":519921,\"journal\":{\"name\":\"Journal of physiological investigation\",\"volume\":\"67 2\",\"pages\":\"88-102\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of physiological investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ejpi.EJPI-D-23-00031\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/4/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of physiological investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ejpi.EJPI-D-23-00031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
摘要:传统中药处方步阳黄芪汤(BHD)能有效治疗动脉粥样硬化。然而,BHD在动脉粥样硬化中的作用机制仍不清楚。我们的目的是确定 BHD 是否能通过改变动脉粥样硬化小鼠体内与微生物相关的代谢变化来缓解动脉粥样硬化。我们用缺乏载脂蛋白E的小鼠建立了动脉粥样硬化模型,并以8.4克/千克/天和16.8克/千克/天的剂量通过灌胃给药12周。对动脉粥样硬化斑块的大小、组成、血清脂质谱和炎症细胞因子进行了评估。通过液相色谱-质谱联用技术和 16S rRNA 基因测序技术分别对代谢组和微生物群概况进行了机理分析。此外,还利用斯皮尔曼分析法对肠道微生物群和动脉粥样硬化相关代谢参数进行了相关分析。接受BHD治疗的动脉粥样硬化小鼠斑块面积缩小、主动脉腔闭塞和主动脉根部脂质积聚减少。九种受干扰的血清代谢物得到了显著恢复,微生物群在科和属一级的相对丰度也得到了显著恢复,但在门一级的相对丰度却没有恢复。肠道微生物组的改善与代谢物水平的改善呈强负相关。通过调节改变的肠道微生物群和紊乱的代谢物,BHD 治疗可有效减缓动脉粥样硬化的进展。
Buyang Huanwu Decoction Alleviates Atherosclerosis by Regulating gut Microbiome and Metabolites in Apolipoprotein E-deficient Mice fed with High-fat Diet.
Abstract: The traditional Chinese herbal prescription Buyang Huanwu decoction (BHD), effectively treats atherosclerosis. However, the mechanism of BHD in atherosclerosis remains unclear. We aimed to determine whether BHD could alleviate atherosclerosis by altering the microbiome-associated metabolic changes in atherosclerotic mice. An atherosclerotic model was established in apolipoprotein E-deficient mice fed high-fat diet, and BHD was administered through gavage for 12 weeks at 8.4 g/kg/d and 16.8 g/kg/d. The atherosclerotic plaque size, composition, serum lipid profile, and inflammatory cytokines, were assessed. Mechanistically, metabolomic and microbiota profiles were analyzed by liquid chromatography-mass spectrometry and 16S rRNA gene sequencing, respectively. Furthermore, intestinal microbiota and atherosclerosis-related metabolic parameters were correlated using Spearman analysis. Atherosclerotic mice treated with BHD exhibited reduced plaque area, aortic lumen occlusion, and lipid accumulation in the aortic root. Nine perturbed serum metabolites were significantly restored along with the relative abundance of microbiota at the family and genus levels but not at the phylum level. Gut microbiome improvement was strongly negatively correlated with improved metabolite levels. BHD treatment effectively slows the progression of atherosclerosis by regulating altered intestinal microbiota and perturbed metabolites.